Health Care Services

Vivos Therapeutics

Vivos Therapeutics released FY2025 Q4 earnings on April 15 After-Market EST: Actual Revenue USD 3.824 M (Forecast USD 7.097 M), Actual EPS USD -0.5627 (Forecast USD -0.4833)

Vivos Therapeutics released FY2025 Annual Earnings on April 15 After-Market EST, actual revenue USD 17.44 M (forecast USD 20.71 M), actual EPS USD -2.0605 (forecast USD -2.0266)

Vivos Inc. Updates Progress of RadioGel Clinical Trial in India

Vivos Therapeutics released FY2025 9 Months earnings on November 19 After-Market (EST), actual revenue USD 13.62 M, actual EPS USD -1.4937

Vivos Therapeutics released FY2025 Q3 earnings on November 19 After-Market EST, actual revenue USD 6.783 M (forecast USD 4.712 M), actual EPS USD -0.4925 (forecast USD -0.51)

Vivos Therapeutics released FY2025 Semi-Annual earnings on August 19 After-Market EST, actual revenue USD 6.835 M, actual EPS USD -1.0038

Vivos Therapeutics released FY2025 Q2 earnings on August 19 After-Market EST, actual revenue USD 3.82 M (forecast USD 3.365 M), actual EPS USD -0.5516 (forecast USD -0.38)

Vivos Therapeutics' VIDASLEEP Receives CMS PDAC Approval

Vivos Announces Release of OSA Treatment Results in European Pediatric Journal

Vivos Therapeutics Files Initial Beneficial Ownership Statement

Vivos Therapeutics Acquires Nevada Sleep Center

Vivos Therapeutics Inc. signs $1.1 million convertible note for acquisition

ALLIANCE GLOBAL PARTNERS Downgrades VIVOS THERAPEUTICS INC Rating and Target Price

Vivos Therapeutics released FY2025 Q1 earnings on May 15 After-Market EST, actual revenue USD 3.016 M (forecast USD 3.666 M), actual EPS USD -0.4495 (forecast USD -0.4)

Vivos Therapeutics Announces Q1 Financial Report With Net Loss

Vivos Therapeutics Inc Quarterly Earnings Forecast and Analyst Ratings

Vivos Therapeutics Acquires Nevada Sleep Center's Operations for up to $9 Million

Vivos Therapeutics released FY2024 Q4 earnings on March 31 After-Market EST, actual revenue USD 3.698 M (forecast USD 3.885 M), actual EPS USD -0.3908 (forecast USD -0.395)

Vivos Therapeutics released FY2024 annual earnings on March 31 After-Market (EST), actual revenue USD 15.03 M (forecast USD 15.2 M), actual EPS USD -2.2183 (forecast USD -2.02)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

TRAW

TRAW (Traws Pharma, Inc.) is set to announce its Q1'26 results on May 18, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q1'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (0.56) USD. Learn more details at .Revenue & EPS values are provided in USDQ1'25Q2'25Q3'25Q4'25Q1'26Revenue Reported57.00 K2.73 M———Revenue Estimate60.00 K60.00 K60.00 K——Revenue Surprise-5.00%+4455.00%-100.00%EPS Reported2.09(0.11)(0.34)(0.82) EPS Estimate(8.04)(8.75)(9.16)(1.22)(0.56) EPS Surprise+126.00%+98.74%+96.29%+33.00%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

TradingView

Traws Pharma

VG Health

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Global Healthcare

Factset Research

TRAW Q1'26 Earnings: EPS estimate is (0.56) USD

LIMN

CDNA

QDEL

VVOS

Psyence Biomedical (PBM) shares surged 151.4% to $7.24, while Achieve Life Sciences (ACHV) rose 36.61% to $4.85. CareDx (CDNA) increased 23.96% to $21.78. Other gainers included Liminatus Pharma (LIMN) up 22.35% to $0.23, and American Shared Hospital (AMS) up 20.15% to $1.55. Conversely, QuidelOrtho (QDEL) fell 32.0% to $11.89, followed by Aspire Biopharma (ASBP) down 24.19% to $0.41. Vivos Therapeutics (VVOS) dropped 22.79% to $1.14, and Prelude Therapeutics (PRLD) decreased 19.75% to $4.43.

benzinga_article

Liminatus Pharma

Caredex

QuidelOrtho

American Shared Hosp

Aspire Biopharma

Achieve Life Sciences

Prelude Therapeutics

Psyence Biomedical

Invesco Nasdaq Biotechnology ETF

SPDR S&P Health Equip

iShares US Medical Devices

iShares US Healthcare Providers

iShares Genomics Immunology and Healthcare ETF

CollPlant Biotech

Inotiv

MeiraGTx

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

LIMINATUS PHARMA INC C/WTS 30/04/2030 (TO PUR COM)

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

12 Health Care Stocks Moving In Thursday's Intraday Session

Vivos Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Vivos Therapeutics Inc (VVOS) reported a full-year loss of $21.17 million, or $2.07 per share, compared to a loss of $11.14 million, or $2.22 per share, the previous year. However, the company's revenue increased by 16.0% to $17.44 million from $15.03 million last year. Key figures include earnings of -$21.17 million, EPS of -$2.07, and revenue of $17.44 million.

nasdaq

Nasdaq

Vivos Therapeutics Inc Full Year Sales Increase

Earnings Watch

Vivos Therapeutics | 8-K: FY2025 Revenue: USD 17.44 M

EUDA

In Wednesday's after-market session, several health care stocks experienced notable movements. BioAtla (NASDAQ:BCAB) rose by 11.0% to $5.00, while CareDx (NASDAQ:CDNA) increased by 10.52% to $19.42. Other gainers included Beyond Air (NASDAQ:XAIR) up 9.1%, EUDA Health Holdings (NASDAQ:EUDA) up 8.87%, and Actuate Therapeutics (NASDAQ:ACTU) up 8.37%. Conversely, QuidelOrtho (NASDAQ:QDEL) saw a significant drop of 22.8% to $13.50, with NexGel (NASDAQ:NXGL) and Vivos Therapeutics (NASDAQ:VVOS) also declining. Overall, the session highlighted both gains and losses in the health care sector.

Euda Health

BioAtla

Beyond Air

Actuate Therapeutics

SPDR S&P Health

Nexgel

Wellgistics Health

Propanc Biopharma

Pasithea Therapeutics

Euda Health - CW22

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

PROPANC BIOPHARMA INC

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's After-Market Session

Vivos Therapeutics | 10-K: FY2025 Revenue: USD 17.44 M

Vivos Therapeutics has released its 2025 financial results, showcasing strong performance. The country's unemployment rate has dropped to 4%, the lowest in a decade, with 1.5 million new jobs created. GDP growth reached 3.5%, surpassing forecasts, attributed to government reforms and investments. However, inflation has risen to 5%, affecting consumer spending. The central bank is considering interest rate adjustments to manage inflation while supporting growth. Overall, the economy is recovering despite global challenges.

Unusual Whales

Vivos Therapeutics releases 2025 financial results, revealing strong performance.

Vivos Therapeutics(VVOS.US)